Posted On: 09/24/2014 12:31:14 PM
Post# of 45016
$PPHM Company News
Apollo slammed on education department review
6:09 p.m. July 14, 2014
- Tom Bemis
Peregrine plunges on test data
4:17 p.m. June 27, 2013
- Russ Britt
Small-cap makes a splash with FDA nod for cancer drug
3:16 p.m. May 20, 2013
- Russ Britt
Peregrine drug shows promise in pancreatic cancer
1:17 p.m. Feb. 13, 2013
- MarketWatch.com
In focus: Bullish, but overbought
8:06 p.m. Jan. 9, 2013
- Lawrence G. McMillan
Hedge funds are bullish on these stocks
11:57 a.m. Dec. 5, 2012
- Insider Monkey
Peregrine, FDA agree on brain-cancer drug study
11:56 a.m. Dec. 5, 2012
- MarketWatch.com
Drug trial contractors improve efficiency
10:24 a.m. Nov. 16, 2012
- MarketWatch.com
Monday’s biggest gaining and declining stocks
6:42 p.m. Sept. 25, 2012
- Greg Morcroft
Tuesday’s biggest gaining and declining stocks
5:09 p.m. Sept. 25, 2012
- Greg Morcroft
Peregrine Pharma down 86% after test data review
8:27 a.m. Sept. 24, 2012
- Steve Gelsi
Peregrine Pharma down 86% in premarket
8:18 a.m. Sept. 24, 2012
- Steve Gelsi
Peregrine reviewing Bavituximab results
7:42 a.m. Sept. 24, 2012
- Greg Morcroft
Some previous Bavituximab data not valid
eregrine
7:42 a.m. Sept. 24, 2012
- Greg Morcroft
Monday’s biggest gaining and declining stocks
2:42 p.m. Sept. 10, 2012
- MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active
11:11 a.m. Sept. 10, 2012
- blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears
6:41 a.m. Sept. 10, 2012
- MarketWatch
Peregrine rallies on bavituximab lung-cancer data
1:29 p.m. Sept. 7, 2012
- MarketWatch.com
Monday’s biggest gaining & declining stocks
2:53 p.m. Aug. 27, 2012
- MarketWatch
Peregrine Pharma slides 12% after negative report
2:21 p.m. Aug. 27, 2012
- Val Brickates Kennedy
Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog
9:00 a.m. Sept. 10, 2014
- Zacks.com
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q1 2015 Results - Earnings Call Transcript
7:53 p.m. Sept. 9, 2014
- Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC
4:29 p.m. Sept. 9, 2014
- Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals (PPHM) Q1 2015 Results - Earnings Call Webcast
4:25 p.m. Sept. 9, 2014
- Seeking Alpha
Tekmira Pharmaceuticals Corp. Is More Than Just A Short-Term Trade
3:12 p.m. Aug. 27, 2014
- Seeking Alpha
Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies
10:43 a.m. Aug. 12, 2014
- Seeking Alpha
Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog
11:00 a.m. July 15, 2014
- Zacks.com
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q4 2014 Results - Earnings Call Transcript
10:21 p.m. July 14, 2014
- Seeking Alpha
10-K: PEREGRINE PHARMACEUTICALS INC
5:00 p.m. July 14, 2014
- Edgar Online - (EDG = 10Q, 10K)
More on Peregrine fiscal Q4 and fiscal year results
4:26 p.m. July 14, 2014
- Seeking Alpha
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
9:30 a.m. July 14, 2014
- TheStreet.com
First Week Of January 2015 Options Trading For Peregrine Pharmaceuticals (PPHM)
11:09 a.m. May 20, 2014
- TheStreet.com
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
6:00 a.m. May 9, 2014
- TheStreet.com
Peregrine wins law suit
9:24 a.m. May 5, 2014
- Seeking Alpha
Medivation Signs Deal with OncoFusion Therapeutics - Analyst Blog
6:24 p.m. April 24, 2014
- Zacks.com
Interesting PPHM Call Options For June 21st
11:02 a.m. April 23, 2014
- TheStreet.com
Peregrine's Bavituximab has high success rate in animal testing
9:47 a.m. April 7, 2014
- Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue? - Tale of the Tape
8:39 a.m. March 18, 2014
- Zacks.com
Cel-Sci's Multikine - Potential 21st Century Superdrug
5:41 p.m. March 13, 2014
- Seeking Alpha
Peregrine antibodies boost anti-tumor activity in animal studies
9:47 a.m. March 11, 2014
- Seeking Alpha
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015
Financial Results and Recent Developments
4:01 p.m. Sept. 9, 2014
- Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E
Convertible Preferred Stock
4:00 p.m. Sept. 8, 2014
- Marketwire
Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015
Financial Results After Market Close on September 9, 2014
4:01 p.m. Sept. 2, 2014
- Marketwire
Preclinical Data Presented at Annual Immunotherapies and Vaccine
Summit Show That the Combination of Peregrine Pharmaceuticals'
PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce
Breast Cancer Progression
8:03 a.m. Aug. 11, 2014
- Marketwire
Small companies lead the I-O class of Cancer Therapies
8:03 a.m. Aug. 8, 2014
- ACCESSWIRE
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
9:00 a.m. Aug. 1, 2014
- PR Newswire - PRF
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal
Year 2014 Financial Results and Recent Developments
4:01 p.m. July 14, 2014
- Marketwire
Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End
Fiscal 2014 Financial Results After Market on July 14, 2014
4:00 p.m. July 7, 2014
- Marketwire
Technical Scrutiny on Biotech Stocks -- Research on Insmed, Peregrine Pharma, CytRx, and Celldex Therapeutics
6:40 a.m. June 30, 2014
- PR Newswire - PRF
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E
Convertible Preferred Stock
4:00 p.m. June 10, 2014
- Marketwire
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma
8:30 a.m. May 30, 2014
- PR Newswire - PRF
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma
12:41 p.m. May 6, 2014
- PR Newswire - PRF
Peregrine Pharmaceuticals Announces Initiation of an
Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab
and Ipilimumab (Yervoy(R)) in Advanced Melanoma
7:31 a.m. April 23, 2014
- Marketwire
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS
12:28 p.m. April 10, 2014
- PR Newswire - PRF
Data Presented at AACR Support Potential of Peregrine's PS-Targeting
Immunotherapy Bavituximab to Enhance Anti-Tumor and
Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in
Models of Melanoma and Colon Cancer
11:01 a.m. April 9, 2014
- Marketwire
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
1:15 p.m. April 8, 2014
- PR Newswire - PRF
Data Presented at AACR Support Potential of Combining Peregrine's
PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung
Cancer
8:04 a.m. April 7, 2014
- Marketwire
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for
Presentation at AACR 2014 Annual Meeting
4:01 p.m. April 1, 2014
- Marketwire
Presentation at Annual Society of Surgical Oncology Meeting Updates
Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's
Bavituximab in Combination With Sorafenib in Liver Cancer
8:02 a.m. March 14, 2014
- Marketwire
Preclinical Data Presentations at Keystone Symposia Highlight Broad
Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting
Antibodies
8:02 a.m. March 13, 2014
- Marketwire
Apollo slammed on education department review
6:09 p.m. July 14, 2014
- Tom Bemis
Peregrine plunges on test data
4:17 p.m. June 27, 2013
- Russ Britt
Small-cap makes a splash with FDA nod for cancer drug
3:16 p.m. May 20, 2013
- Russ Britt
Peregrine drug shows promise in pancreatic cancer
1:17 p.m. Feb. 13, 2013
- MarketWatch.com
In focus: Bullish, but overbought
8:06 p.m. Jan. 9, 2013
- Lawrence G. McMillan
Hedge funds are bullish on these stocks
11:57 a.m. Dec. 5, 2012
- Insider Monkey
Peregrine, FDA agree on brain-cancer drug study
11:56 a.m. Dec. 5, 2012
- MarketWatch.com
Drug trial contractors improve efficiency
10:24 a.m. Nov. 16, 2012
- MarketWatch.com
Monday’s biggest gaining and declining stocks
6:42 p.m. Sept. 25, 2012
- Greg Morcroft
Tuesday’s biggest gaining and declining stocks
5:09 p.m. Sept. 25, 2012
- Greg Morcroft
Peregrine Pharma down 86% after test data review
8:27 a.m. Sept. 24, 2012
- Steve Gelsi
Peregrine Pharma down 86% in premarket
8:18 a.m. Sept. 24, 2012
- Steve Gelsi
Peregrine reviewing Bavituximab results
7:42 a.m. Sept. 24, 2012
- Greg Morcroft
Some previous Bavituximab data not valid
eregrine 7:42 a.m. Sept. 24, 2012
- Greg Morcroft
Monday’s biggest gaining and declining stocks
2:42 p.m. Sept. 10, 2012
- MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active
11:11 a.m. Sept. 10, 2012
- blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears
6:41 a.m. Sept. 10, 2012
- MarketWatch
Peregrine rallies on bavituximab lung-cancer data
1:29 p.m. Sept. 7, 2012
- MarketWatch.com
Monday’s biggest gaining & declining stocks
2:53 p.m. Aug. 27, 2012
- MarketWatch
Peregrine Pharma slides 12% after negative report
2:21 p.m. Aug. 27, 2012
- Val Brickates Kennedy
Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog
9:00 a.m. Sept. 10, 2014
- Zacks.com
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q1 2015 Results - Earnings Call Transcript
7:53 p.m. Sept. 9, 2014
- Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC
4:29 p.m. Sept. 9, 2014
- Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals (PPHM) Q1 2015 Results - Earnings Call Webcast
4:25 p.m. Sept. 9, 2014
- Seeking Alpha
Tekmira Pharmaceuticals Corp. Is More Than Just A Short-Term Trade
3:12 p.m. Aug. 27, 2014
- Seeking Alpha
Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies
10:43 a.m. Aug. 12, 2014
- Seeking Alpha
Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog
11:00 a.m. July 15, 2014
- Zacks.com
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q4 2014 Results - Earnings Call Transcript
10:21 p.m. July 14, 2014
- Seeking Alpha
10-K: PEREGRINE PHARMACEUTICALS INC
5:00 p.m. July 14, 2014
- Edgar Online - (EDG = 10Q, 10K)
More on Peregrine fiscal Q4 and fiscal year results
4:26 p.m. July 14, 2014
- Seeking Alpha
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
9:30 a.m. July 14, 2014
- TheStreet.com
First Week Of January 2015 Options Trading For Peregrine Pharmaceuticals (PPHM)
11:09 a.m. May 20, 2014
- TheStreet.com
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
6:00 a.m. May 9, 2014
- TheStreet.com
Peregrine wins law suit
9:24 a.m. May 5, 2014
- Seeking Alpha
Medivation Signs Deal with OncoFusion Therapeutics - Analyst Blog
6:24 p.m. April 24, 2014
- Zacks.com
Interesting PPHM Call Options For June 21st
11:02 a.m. April 23, 2014
- TheStreet.com
Peregrine's Bavituximab has high success rate in animal testing
9:47 a.m. April 7, 2014
- Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue? - Tale of the Tape
8:39 a.m. March 18, 2014
- Zacks.com
Cel-Sci's Multikine - Potential 21st Century Superdrug
5:41 p.m. March 13, 2014
- Seeking Alpha
Peregrine antibodies boost anti-tumor activity in animal studies
9:47 a.m. March 11, 2014
- Seeking Alpha
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015
Financial Results and Recent Developments
4:01 p.m. Sept. 9, 2014
- Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E
Convertible Preferred Stock
4:00 p.m. Sept. 8, 2014
- Marketwire
Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015
Financial Results After Market Close on September 9, 2014
4:01 p.m. Sept. 2, 2014
- Marketwire
Preclinical Data Presented at Annual Immunotherapies and Vaccine
Summit Show That the Combination of Peregrine Pharmaceuticals'
PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce
Breast Cancer Progression
8:03 a.m. Aug. 11, 2014
- Marketwire
Small companies lead the I-O class of Cancer Therapies
8:03 a.m. Aug. 8, 2014
- ACCESSWIRE
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
9:00 a.m. Aug. 1, 2014
- PR Newswire - PRF
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal
Year 2014 Financial Results and Recent Developments
4:01 p.m. July 14, 2014
- Marketwire
Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End
Fiscal 2014 Financial Results After Market on July 14, 2014
4:00 p.m. July 7, 2014
- Marketwire
Technical Scrutiny on Biotech Stocks -- Research on Insmed, Peregrine Pharma, CytRx, and Celldex Therapeutics
6:40 a.m. June 30, 2014
- PR Newswire - PRF
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E
Convertible Preferred Stock
4:00 p.m. June 10, 2014
- Marketwire
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma
8:30 a.m. May 30, 2014
- PR Newswire - PRF
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma
12:41 p.m. May 6, 2014
- PR Newswire - PRF
Peregrine Pharmaceuticals Announces Initiation of an
Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab
and Ipilimumab (Yervoy(R)) in Advanced Melanoma
7:31 a.m. April 23, 2014
- Marketwire
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS
12:28 p.m. April 10, 2014
- PR Newswire - PRF
Data Presented at AACR Support Potential of Peregrine's PS-Targeting
Immunotherapy Bavituximab to Enhance Anti-Tumor and
Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in
Models of Melanoma and Colon Cancer
11:01 a.m. April 9, 2014
- Marketwire
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
1:15 p.m. April 8, 2014
- PR Newswire - PRF
Data Presented at AACR Support Potential of Combining Peregrine's
PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung
Cancer
8:04 a.m. April 7, 2014
- Marketwire
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for
Presentation at AACR 2014 Annual Meeting
4:01 p.m. April 1, 2014
- Marketwire
Presentation at Annual Society of Surgical Oncology Meeting Updates
Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's
Bavituximab in Combination With Sorafenib in Liver Cancer
8:02 a.m. March 14, 2014
- Marketwire
Preclinical Data Presentations at Keystone Symposia Highlight Broad
Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting
Antibodies
8:02 a.m. March 13, 2014
- Marketwire
(0)
(0)
